IPH Innate Pharma SA Class A

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:

 

Total number of shares outstanding:79,294,402 ordinary shares
 6,784 Preferred Shares 2016



7,581 Preferred Shares 2017
Total number of theoretical voting rights (1):



Total number of exercisable voting rights (2):
80,087,342



80,068,767

 

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at -pharma.com

 

Information about Innate Pharma shares:

ISIN code

Ticker code

LEI
FR0010331421



Euronext: IPH Nasdaq: IPHA



9695002Y8420ZB8HJE29

 

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website -france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:
Investors







Innate Pharma



Henry Wheeler



Tel.: 4



 Media







Innate Pharma



Tracy Rossin (Global/US)



Tel.:











ATCG Press



Marie Puvieux (France)



Tel.: +33 (0)9 81 87 46 72



Attachment



EN
23/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Innate Pharma SA Class A

Delphine Brault ... (+2)
  • Delphine Brault
  • Quentin Borie

ODDO BHF Small & MIDCAP MORNING NEWS - 03/21/2024

GTT boasts a secure growth profile with enhanced visibility on the back of high-quality backlog. With over € 1.8bn in secured revenues, we are anticipating an EBITDA CAGR of 22% over 2023-26. Growth drivers were confirmed (LNG fuel, hydrogen, digital services) and the news flow should remain favourable (future orders). The valuation remains modest (13x EBITDA vs 13.4x for historical ratio) in light of the anticipating growth (0.6x 2023-26 CAGR). Our target price stands at € 170 exclu...

Delphine Brault ... (+2)
  • Delphine Brault
  • Quentin Borie

ODDO BHF Small & MIDCAP MORNING NEWS - 21/03/2024

GTT présente un profil de croissance sécurisé avec une visibilité renforcée à l’appui d’un backlog de qualité. Fort d’un CA sécurisé de plus de 1.8 Md€, nous tablons sur un TMVA 2023/26 de l’EBITDA de +22%. Les relais de croissance sont confirmés (GNL Carburant, Hydrogène, Services digitaux) et le newsflow devrait demeurer bien orienté (futures commandes). La valorisation reste modeste (13x l’EBITDA vs 13.4x pour les références historiques) au regard de la croissance attendue (0.6x TM...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Innate Pharma : Lacutamab and ANKET key to newsflow in the short term

>Financial visibility out to end-2025 - Innate Pharma this morning reported its figures for 2023. Operating revenue for the period came in at € 61.6m (+7% y-o-y), stemming mainly from the recognition of payments received in the context of its collaborations (+4.7% y-o-y at € 52m) and the research tax credit (€ 9.7m). Operating expenses remain stable at € 74.3m, for an operating loss of -€ 12.7m (vs -€ 16.4m in 2022 excluding asset write-down charges).Cash at end-...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Innate Pharma : Lacutamab et ANKET au cœur du newsflow à court terme

>Visibilité financière jusqu’à fin 2025 - Innate Pharma publie ce matin ses chiffres au titre de l’exercice 2023. Les revenus opérationnels de la période se montent à 61.6 M€ (+7% yoy) provenant essentiellement de la reconnaissance de paiements reçus dans le cadre de ses accords de collaborations (+4.7% yoy à 52 M€) et du crédit impôt recherche (9.7 M€). Les charges opérationnelles demeurent stables à 74.3 M€ pour une perte opérationnelle qui ressort à -12.7 M€ (vs -1...

 PRESS RELEASE

Innate Pharma présente ses résultats financiers et l'avancée de son po...

MARSEILLE--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui ses résultats financiers consolidés au 31 décembre 2023. Les comptes consolidés sont joints au présent communiqué. « Nous avons clos l’année 2023 avec un horizon de trésorerie qui s’étend jusqu’à fin 2025 et avons franchi cette année des étapes importantes dans le développement de notre portefeuille de produits, » commente Hervé Brailly, Président du Directoire ad interim d’Innate Pharma. « Nous avons communiqué les résultats positifs de l...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch